



## Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

February 18, 2016

BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 18, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:

- **2016 RBC Capital Markets Global Healthcare Conference**

Wednesday, February 24, 2016 at 4:05 p.m. Eastern Time  
The New York Palace Hotel, New York, NY

- **36th Annual Cowen and Company Healthcare Conference**

Monday, March 7, 2016 at 1:20 p.m. Eastern Time  
The Boston Marriott Copley Place, Boston, MA

Live audio webcasts of the presentations can be accessed through the Calendar of Events section of the Company's website at [investors.ocutx.com](http://investors.ocutx.com). Replays of the webcasts will be available on the Company's website for two weeks following each presentation.

### About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidate, DEXTENZA™, is in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and in Phase 2 clinical development for inflammatory dry eye disease. An NDA for the post-operative ocular pain indication has been accepted by the FDA with a PDUFA date of July 24, 2016. A third Phase 3 clinical trial is being conducted for post-operative ocular inflammation and pain. For glaucoma and ocular hypertension, OTX-TP (sustained release travoprost) intracanalicular depot, has completed a Phase 2b clinical trial. Ocular Therapeutix is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160218005306/en/>

Source: Ocular Therapeutix, Inc.

### Investors

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

[bsmith@ocutx.com](mailto:bsmith@ocutx.com)

or

Burns McClellan on behalf of Ocular Therapeutix

Steve Klass, 212-213-0006

[sklass@burnsmc.com](mailto:sklass@burnsmc.com)

or

### Media

Ocular Therapeutix, Inc.

Scott Corning

Vice President of Sales and Marketing

[scorning@ocutx.com](mailto:scorning@ocutx.com)